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Abstract Amoebiasis is one of the major public health prob-
lems in developing countries. In spite of the availability of an
effective drug and absence of overt drug resistance, the dis-
ease is still prevalent among large population and spread over
a number of countries. It is caused by the protist parasite
Entamoeba histolytica that essentially infects humans, though
other species that infect a few animals have been reported. A
number of molecular techniques have recently been devel-
oped. These have helped in understanding biological process-
es in E. histolytica and in the identification of key molecules
that are involved in amoebic virulence and invasion. More-
over, developments in the area of disease and invasion models
have allowed understanding of these processes at molecular
level and circumvented lack of a good animal model of am-
oebiasis. All these knowledge will help us to design better
therapeutics and allow us to control this important disease.
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Entamoeba histolytica was first described by Schaudinn in
1903 as the Entamoeba species associated with human dys-
entery [1]. The species found in healthy individuals was orig-
inally named as Entamoeba coli. The concept of the two
species of Entamoeba, one involved in the human disease
and the other, a nonpathogenic form though capable of infect-
ing human, was felt even in early days [2]. After the advent of
molecular tools, it became clear that there are two morpholog-
ically indistinguishable closely related species, E. histolytica
(pathogenic) and Entamoeba dispar (nonpathogenic) [3•, 4].
Not all E. histolytica infected individuals display invasive
disease as a large fraction of infected individuals remains
healthy, although capable of spreading infection [5, 6]. It is
still not clear under what conditions E. histolytica cells turn
invasive. Both parasite and host factors may have important
roles to play in tissue invasion. However, no invasive disease
has been clearly documented in individuals who are infected
withE. dispar, though there are occasional reports ofE. dispar
causing amoebiasis [7–10]. Since it is difficult to rule out
complete absence of E. histolytica in these studies, further
validation is required. Currently, the disease caused by
E. histolytica is referred to as Bamoebiasis^ and includes both
intestinal and extraintestinal forms. In this article, we will not
describe pathophysiology and epidemiology of the disease as
these have recently been covered [11–13, 14•, 15–17].
E. histolytica exists in two developmental stages, four-
nucleated cyst form and the trophozoites. Infection is initiated
by ingestion of the cysts through food or water. Cysts can
survive acidic environment of the stomach and excyst to form
trophozoites in the terminal ileum or colon. On the other hand,
trophozoites are highly motile, multiply by binary fission, and
encyst in the colon. Cysts excreted out in the feces can infect
new individuals through contamination of food and water.
Unlike many other parasites, E. histolytica multiplies and dif-
ferentiates only in humans. The life cycle described here is
generally seen in most individuals who do not show any
symptoms of invasive disease. However, in a fraction of in-
fected humans, amoebic trophozoites do become invasive,
spreading to the epithelial tissue or blood vessel after making
This article is part of the Topical Collection on Parasitology
* Alok Bhattacharya
alok.bhattacharya@gmail.com
1 School of Life Sciences, Jawaharlal Nehru University, NewMehrauli
Road, Near Munirka, New Delhi, Delhi 110067, India
2 School of Environmental Sciences, Jawaharlal Nehru University,
NewMehrauli Road, Near Munirka, New Delhi, Delhi 110067, India
Curr Clin Micro Rpt (2015) 2:143–154
DOI 10.1007/s40588-015-0023-1
lesions through colonic layer. Therefore, the steps that play a
critical role in pathogenesis are attachment to the colonic wall
and destruction of basement membrane and tissues. Molecular
analysis of pathogenic mechanisms has been possible due to
unprecedented development, not only in our ability to identify,
purify, and characterize individual molecules but also in our
ability to manipulate parasite cells to express desired proteins
and/or downregulate the expression of a specific gene.
Though there has not yet been an animal model that mimics
closely human disease, many in vitro cell-based assays,
ex vivo systems, and tissue mimics have been developed.
These can be used, in addition to animal models, to answer
some of the questions related to pathogenesis. These studies
have helped to identify some of the pathogenesis-related mol-
ecules and establish the role of some of the identified mole-
cules in amoebiasis.
Host Genotype and Susceptibility to E. histolytica
Infection
It has been recognized for some time that not all individuals
are equally susceptible to infection and invasive disease as a
result of an exposure to E. histolytica [17]. Only those humans
who carry susceptible allele are more likely to get invasive
disease. The host can contribute in number of ways to deter-
mine the outcome of E. histolytica infection. The gut environ-
ment may be highly favorable for E. histolytica to either
excyst or multiply. Among other host factors, human intestinal
microflora is thought to be involved in amoebic invasion as it
plays an important role in metabolism and host immunity.
Early studies have shown a clear relationship between bacte-
rial association and pathogenesis of E. histolytica [18]. The
trophozoites multiply in the lumen of the gut and obtain food
through phagocytosis of the resident flora. It is therefore not
surprising that gut microbiome has tremendous influence on
amoebic physiology. Co-culturing of the trophozoites of
E. histolytica with E. coli 055 or Shigella dysenteriae showed
that these bacteria could change the cytopathic effect of
E. histolytica and increase the expression of Gal/GalNAc lec-
tin and cysteine proteinase activity [19]. Qualitative and quan-
titative alterations in gut flora have been reported in many
intestinal diseases [20–22], but there are very few reports cur-
rently available on the status of gut flora in E. histolytica-
infected individuals. Studies with selected bacterial species
have shown that there is a significant decrease in absolute
number of Bacteroides, Clostridium coccoides, Clostridium
leptum, Lactobacillus, and Campylobacter and an increase
in Bifidobacterium, while there is no change in Ruminococcus
compared to healthy patients [23•, 24], indicating that some of
the pathology observed during amoebiasis may be driven by
an altered microbiome.
The host genotype may determine the nature of intestinal
epithelial lining, thereby influencing the ability of
E. histolytica to invade epithelial tissues. Since HLA-allelic
polymorphism is associated with diversity in immune re-
sponse, attempts have been made to associate susceptibility
to amoebic infection with the presence of a specific HLA
allele. Protection against amoebic infection was observed with
HLA class II allele DQB1*0601/DRB1*1501 haplotype.
Moreover, among heterozygous and homozygous haplotypes,
the former were ten times less likely to be infected than the
latter [25]. Genome-wide association studies have been used
to identify susceptibility alleles for E. histolytica infection. In
one of these studies, a SNP in leptin receptor, associated with
invasive disease, was identified [26•]. Adipocytokine leptin
was shown to have a protective role in mucosal resistance to
E. histolytica infection. The Q223R allele showed fourfold
higher susceptibility in children [26•, 27] which is thought to
be due to attenuated STAT3 signaling. Moreover, leptin or
leptin receptor deficient mice were found to be also more
susceptible to infection [28]. Mice with non-functional leptin
receptor were highly susceptible to Entamoeba-mediated mu-
cosal destruction. Both STAT 3 and SHP2/ERK signaling are
involved in leptin-mediated resistance. Host complement sys-
tem also plays a protective role against Entamoeba infection;
however, the pathogen has shown to develop a reversible re-
sistance to complement lysis. A cell surface calreticulin-like
protein that binds human C1q has been identified and is likely
to play a role in complement resistance [29]. Matrix metallo-
proteinases (MMPs) play an important role in the invasive
process. Genes encoding MMP 1 and MMP 3 were found to
be overexpressed in colonic biopsies of patients with acute
colitis [30]. Metallosurface protease EhMSP1, a novel M8
surface family metalloproteinase, was also shown to be in-
volved in regulating amoebic adherence as silencing of the
gene increases adherence to Chinese hamster ovary cell
monolayer while having less impact on cell motility, phago-
cytosis, and monolayer destruction [31].
Molecules Involved in Pathogenesis
E. histolytica is a highly motile cell and motility is a pivotal
factor for invasion. Trophozoites interact with the extracellular
matrix and adhere to human cells as a result of binding to
surface receptors. Amoebic motility appears to be one of the
key features needed during tissue invasion. E. histolytica has
an actin-rich cytoskeleton which plays a critical role by pro-
viding the necessary motive force during invasion and cytol-
ysis. Some of the molecules that have been identified to mod-
ulate cytoskeleton are myosins (myosin II and myosin IB) [32,
33], gelation factor ABP 120 [34], small GTPAse Rac G [35],
and PAK [36]. In general, any interference with cytoskeleton-
associated molecules in E. histolytica blocks virulence [37].
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Cell Surface Molecules of E. histolytica
Lipophosphopeptidoglycan and Other GPI-Anchored
Cell Surface Molecules Trophozoites abundantly express
l i p o pho s phop e p t i d o g l y c a n s (LPPG ) , a ma j o r
glycosylphosphatidylinositol (GPI) containing complex car-
bohydrate on their surface [38, 39]. These molecules are
thought to make up the glycocalyx layer of E. histolytica
and constitute the major surface component that interacts with
the target cells, including human tissues, through terminal
sugar molecules. Fresh trophozoites isolated from patients
displayed higher thickness of LPPG-based glycocalyx layer
[40]. Conversely, LPPG was not detected in nonpathogenic
E. dispar [41], indicating an important role of LPPG in amoe-
bic pathogenesis. LPPG is also thought to initiate inflamma-
tory and immune response in animal and in patients [42•, 43].
EhLPPG can recognize TLR-2 and TLR-4 on the surface of
macrophage and dendritic cells stimulating the expression of
cytokines and co-stimulatory molecules [43, 44]. It mediates
pro-inflammatory response after it enters the intestinal barrier
[45]. Antibodies against LPPG prevent disease progression in
animal models of amoebiasis. It has also been suggested as a
possible ligand of natural killer T cells (NKT). The purified PI
moiety of this molecule was found to induce IFN gamma, but
not IL4 production by NKT cells [42•]. Exposure to LPPG
also reduced the severity of liver infection in mouse models.
All these results suggest that LPPG could be a good vaccine
and therapeutic candidate for amoebiasis.
The E. histolytica cell surface displays a number of other
GPI-anchored molecules including subunits of Gal/GalNAc
lectin described below. Many of these molecules may have a
role in attachment and virulence of E. histolytica. Though
most of the molecules have not been characterized in relation
to pathogenesis, their role in virulence has been demonstrated
using indirect approaches. Reduction of cell surface GPI-
anchored glycoconjugates was achieved by downregulating
the expression of either mannosyltransferase or GlcNAc
deacetylase [46, 47]. In both cases, the cells lost their ability
to invade, as determined by different assays of pathogenesis,
suggesting that GPI-anchored molecules play a crucial role in
amoebic pathogenesis.
Gal/GalNAc Lectin Galactose/N-acetyl D-galactosamine-
inhibitable (Gal/GalNAc) lectin is one of the major cell sur-
face molecules that is involved in adherence of E. histolytica
to basement membrane and epithelial tissues [48]. It has been
proposed as a major vaccine candidate and a key molecule in
amoebic pathogenesis [49–56]. The heavy subunit (Hgl) of
the Gal/GalNAc lectin is a type 1 transmembrane protein
while the light (Lgl) and intermediate (Igl) subunits have
GPI anchors [57]. Genome analyses revealed redundancy in
the genes encoding different subunits of the lectin. The
orthologs of Hgl and Lgl subunits have been identified in
the nonpathogenic E. dispar and in other Entamoeba species
(E. invadens, E. moshkovskii, and E. terrapinae) [58]. There-
fore, it appears that in addition to pathogenesis, these mole-
cules may have a basic role in Entamoeba biology. The role of
these molecules in attachment to target cells and resistance to
complement has been amply demonstrated using monoclonal
antibodies that were able to block attachment and subsequent
invasion [59]. Moreover, dominant-negative phenotype of the
Hgl subunit of the Gal/GalNAc lectin showed reduced cell
adhesion activity and tissue invasion capacity, indicating a
signaling pathway involving the cell-surface lectin molecules
[60]. Although details of the pathway are not clear, it is
thought that Gal/GalNAc lectin initiates signaling
through the participation of phosphoinositides, lipid
rafts, and cytosolic Ca2+ [61].
Other Cell SurfaceMoleculesA number of other cell surface
molecules with roles in amoebic pathogenesis have been iden-
tified and partially characterized. Among these, the EhCP-
ADH complex has been studied most extensively [62–67].
EhCP-ADH complex encodes two proteins, a cysteine prote-
ase, EhCP112, and an adhesion protein, EhADH112 [68].
These proteins are involved in invasion, phagocytosis, and
cytolysis, and the complex has been suggested to be a poten-
tial vaccine candidate [69]. In a screen to identify amoebic cell
surface molecules that participate in phagocytosis, a serine-
rich protein (SREHP) was identified [70]. Though the precise
function of this abundant cell surface protein is not clear, re-
sults suggest that SREHP is likely to be part of the PI3K
pathway [71]. Genomic polymorphisms in SREHP gene have
been noted [72]. A lysine and glutamic acid-rich cell surface
adhesionmolecule KERP1 is reported to be involved in amoe-
bic virulence [73]. The nature of the ligands and the mecha-
nisms by which these molecules function is not clear. Genome
analysis has revealed a large array of putative, cell surface
transmembrane kinases (TMKs) in E. histolytica. These have
been categorized into nine families and a few have been func-
tionally characterized.Members of EhTMKB1 family, such as
EhTMKB1-9 and EhTMKB1-2, have been shown to be in-
volved in cellular proliferation and serum response [74, 75].
PATMK (EhTMKB3-96) co-localized with human erythro-
cy tes a t the s i t e o f contac t and i s involved in
erythrophagocytosis and was identified during screening for
proteins involved in the recognition and ingestion of apoptotic
cells [76•]. TMK39 also participates in amoebic phagocytosis
though in non-overlapping manner [77]. On the other hand,
TMK54 interfered with the growth of E. histolytica and may
have indirect effect on virulence as it regulated the expression
of heavy subunit of Gal/GalNAc lectin [77].
It is not clear whether adhesion to target cells and phago-
cytosis require the participation of only a few key molecules
or the combined action of a large number of cell surface com-
ponents. It appears likely that participation of a large number
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of molecules is needed, as blocking any one molecule gives
only partial inhibition. The rules by which different molecules
collaborate with each other and the various pathways that are
involved in transducing signals after attachment to target cells
need to be understood.
Secreted Molecules Involved in Pathogenesis
Damage of extracellular matrix, tissues, and cells are the hall-
mark of amoebic pathophysiology. As pointed out in the pre-
vious section, contact with E. histolytica cells is one of the
primary events in the initiation of invasion. Besides direct
contact, amoeba also invades by degrading or damaging the
relevant tissues/cells by secreting a number of enzymes that
are capable of digesting even hard tissues or extracellular ma-
trices. Some of the well-known enzymes are described here.
Cysteine Proteases Cysteine proteases constitute the major
class of secreted hydrolases of Entamoeba. Genome mining
helped to identify about 50 genes coding for cysteine pepti-
dases belonging to C1 papain superfamily, C2 (calpain-like
cysteine proteases), C19 (ubiquitinyl hydrolase), C48 (Ulp1
peptidase), C54 (autophagin), and C65 (otubain), respectively
(reviewed in Clark et al. [78]). Out of these, only 20 cysteine
peptidase genes are expressed in E. histolytica, of which
EhCP1, EhCP2, and EhCP5 constitute 90 % of the transcripts
arising out of all cysteine proteases (CPs) [79•]. A number of
experiments suggest that CPs play a major role in amoebic
pathogenicity [80–86, 87•, 88, 89]. CPs can degrade extracel-
lular matrix (ECM) proteins as well as mucin 2, a major com-
ponent of colon mucus [90]. They also invade the immune
system by degrading host antibodies and complement [91].
Among different CPs, EhCP5 has emerged as one of the major
virulence-related CP. EhCP5 is present on the surface of the
amoeba and is thought to participate in the disruption of the
mucin barrier of the colon [92]. It also interacts with the co-
lonic epithelial cell integrins, thus activating NFkappaβ-
mediated inflammatory response in host cells [93]. Overex-
pression of cysteine protease genes ehcp-b8, ehcp-b9, and
ehcp-c13 results in transformation of a nonpathogenic
E. histolytica to more pathogenic type [94]. CPs may have a
direct role during tissue invasion and cell killing. Overexpres-
sion of cysteine proteinase 2, EhCP2, increases amoeba-
induced monolayer destruction in vitro but has no effect on
amoebic liver abscess (ALA) formation [86]. CP-specific in-
hibitor, trans-epoxysuccinyl-L-leucyl-amido-4-guanidino-bu-
tane (E-64), interfered with EhCP-A5 gene expression, thus
showing involvement of CPs in ALA formation [85]. EhCP5
has interleukin-1b convertase activity suggesting that these
enzymes use a mechanism that is novel in microbial pathoge-
nicity [95]. A recent report by Thibeaux et al. showed that
EhCP-A5 activates matrix metalloproteinases pro-MMP3 by
cleaving. This in turn activates pro-MMP1 resulting in muco-
sal invasion. Ex vivo incubation with recombinant EhCP-A5
was able to rescue the deficient trophozoites, thus showing
that cysteine proteases regulate the activities of MMPs for
colonic invasion [96].
All these studies clearly show that CPs are major virulence-
associated molecules and are a good target for developing
novel therapies for amoebiasis. Cysteine protease EhCP4 has
a key role in invasive amoebiasis and therefore a potential
therapeutic target [97]. Recombinant EhCP1 has been used
to identify a potent inhibitor of amoebic invasion in human
colonic model [98]. High throughput screens for the identifi-
cation of CP inhibitors have been developed, and small inhib-
itor molecules that blocked CP activity were identified.
Auronafin is several times more potent than metronidazole
and a few other inhibitors, such as paromomycin and
tinidazole against E. histolytica. Auronafin works by altering
the nucleotidemetabolism, signal transduction, andmitosis. In
the mouse models of amoebic colitis and hamster model of
amoebic liver abscess, oral auronafin markedly decreased he-
patic damage and inflammatory response [99••, 100], thus
providing a potential drug to treat amoebiasis.
Amoebapores Amoebapores are a family of pore-forming
peptides that is thought to be involved in cytolysis of target
cells. There are three different amoebapores (a, b, c) encoded
by separate genes, and these are structurally and functionally
related to granulolysins and natural killer (NK) lysins pro-
duced by mammalian T cells [101•, 102, 103]. Trophozoites
of E. histolytica lacking the major isoform amoebapore A,
whether through antisense inhibition [104••] or epigenetic si-
lencing of the gene [105], became avirulent demonstrating
that this protein plays a key role in pathogenesis. Recent stud-
ies indicate that these peptides are more involved in killing
phagocytosed bacteria or other organisms rather than target
cells/tissues. These are discharged by E. histolytica into
bacteria-containing phagosomes in order to kill and lyse
engulfed microorganisms [106].
Other Molecules Some of the molecules reported to be in-
volved in pathogenesis other than the ones described in the
previous section are lysine and glutamic acid-rich protein
KERP 1 [107], peroxiredoxin [108, 109], and arginase
[110]. Since oxidative stress is harmful for amoeba, it is not
surprising to find some of the enzymes that participate in
removing different O2/H2O2 ions/radicals.
Molecules Involved in Phagocytosis and Cell
Surface-Associated Signaling
Phagocytosis plays a critical role in amoebic pathogenesis.
Therefore, the molecules associated with phagocytic
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pathways would be required for successful amoebic invasion.
Though a number of cell surface molecules, such as Gal/
GalNAc lectin, SREHP, KERP1, and EhCPDH, have been
implicated in the attachment of target cells, it is not clear what
role these play and the nature of signaling event initiated by
these after ligand attachment [17]. It also appears that there is
some sort of specificity in the choice of ligand by a cell surface
receptor. This has particularly been seen in the Gal/GalNAc
lectin where uptake of certain ligand was not inhibited by anti-
lectin antibody [111, 112]. There is a need for detailed studies
on the recognition of different cellular ligands byE. histolytica
and the early signaling events initiated after attachment.
The mechanism of phagocytosis of RBCs by E. histolytica
has been investigated in order to understand the process of
phagocytosis in this organism. Ca2+ signaling was found to
be important, as chelation of intracellular Ca2+ blocked
erythrophagocytosis [113]. A number of calcium-binding pro-
teins, such as EhCaBP1 and EhCaBP3, were identified as key
molecules during erythrophagocytosis. These two molecules
were found to be recruited early to the phagocytic cups. Both
molecules bind actin and, in addition, EhCaBP3 also
interacted with myosin 1B [114], thereby regulating cytoskel-
eton dynamics.
Recent work by Somlata et al. suggests that recruitment of
a C2 domain-containing protein kinase (EhC2PK) at the li-
gand attachment site is one of the early signaling events in
phagocytosis. This leads to recruitment of EhCaBP1 and sub-
sequently actin [115•]. EhCaBP3 joins the phagocytic site
independently. It is suspected that increase in local Ca2+ level
on the attachment of the ligand helps EhC2PK binding to the
PS-containing inner leaflet of the plasma membrane through
C2 domain. The kinase activity of EhC2PK is essential for the
progression of phagocytic cup to phagosome, as overexpres-
sion of a kinase-dead mutant resulted in reduced
erythrophagocytosis [115•]. Since the substrate for EhC2PK
has not been identified, the nature of downstream signaling
pathway propagated through EhC2PK remains unknown.
Since both EhCaBP1 and EhC2PK leave the phagocytic cup
before it closes to form the phagosome, these two molecules
appear to be required primarily in the initial stages of cup
formation and stabilization. On the other hand, EhCaBP3 is
present in nascent phagosomes and is also present along with
myosin 1B at the site of cup closure [114]. It has been specu-
lated that EhCaBP3 is involved both in cup progression as
well as phagosome closure and scission. Therefore, the two
calcium-binding proteins EhCaBP1 and EhCaBP3 have dis-
tinctly different functions. Apart from these two CaBPs, an
alpha kinase EhAK1 is also involved in the amoebic phago-
cytic pathway [116]. EhAK1 phosphorylates actin and thereby
regulates cytoskeletal dynamics. It is recruited at the phago-
cytic cups and is present till phagosomes are fused, but is
absent in nascent phagosomes. A number of approaches, such
as antisense inhibition, overexpression of kinase-dead mutant,
and phosphorylation-defective actin molecules, were used to
demonstrate that EhAK1 participates in phagocytosis. These
results point to a novel pathway of phagocytosis in
E. histolytica, and the key molecules described here offer
good targets for developing novel therapeutics.
A number of other signaling molecules are believed to
participate through interaction of cell surface-signaling mole-
cules with RBCs/bacteria/epithelial cells/ECM. These involve
cytoskeletal dynamics and are important in the pathogenesis
of amoebiasis [117, 118]. Transduction of these signals may
be mediated through heterotrimeric G proteins [119] and sub-
sequently, GTPases, multifunctional kinases, and phospha-
tases may be involved [120]. Some of the known
cytoskeleton-modulating proteins, such as PAK1 [36]; EhFP4
[121]; EhGEF1 [122], EhGEF2 [123], and EhGEF3 [124];
myosin 1b [125] and myosin II [126], have also been identi-
fied in E. histolytica, and preliminary functional characteriza-
tion suggests that these also participate in cytoskeleton dy-
namics and consequently phagocytosis in amoeba. However,
detailed mechanisms are still lacking.
Traditional concept about target cell killing and invasion
has been seriously challenged in a recent study. Instead, it has
been suggested that cell killing and invasion follows a process
called trogocytosis, nibbling bits of cells and tissues similar to
that seen in the immune system [127]. Live cells undergo
trogocytosis whereas phagocytosis operates for dead cells.
Since EhC2PK was also found to be involved in trogocytosis,
it appears that it follows the same pathway as phagocytosis.
The conditions that determine whether trogocytosis or phago-
cytosis will take place is not yet clear.
Mucus Layer
Goblet cells in the colonic epithelium secrete mucins into the
lumen, which form a gelatinous barrier and present the first
line of defense against invading pathogens. Studies with
MUC2-deficient mice suggested that mucin layer provides
resistance against infectious colitis by maintaining a balance
between pathogenic and commensal organisms associated
with the mucosal surface [128]. They also help to block ad-
herence of trophozoites to epithelial cells by providing ligands
for the binding of Gal/GalNAc lectin, resulting in competitive
inhibition [48]. CPs are thought to bind less glycosylated re-
gions of the MUC2 polypeptide, facilitating solvation of the
colonic mucus gel and invasion of the colonic epithelial cells
[90]. When these mice were challenged with E. histolytica
trophozoites, it displayed pro-inflammatory response as
shown by increased expression of pro-inflammatory markers
such as TNFα and IFNγ [128]. In the absence ofMUC2, mice
became vulnerable to EhCP-A5-mediated secretory and pro-
inflammatory responses [129]. PGE2 was secreted [130], by
the activation of prostaglandin receptor EP4 [131]. The
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resulting disruption of tight junctions allowed invasion of tro-
phozoites into the basolateral surface of intestinal epithelial
layer [132]. Apart from CPs, other molecules may also be
involved in the disruption of the colonic mucus layer, such
as an Boccludin- like^ protein that is thought to play a role in
pathogenesis [133].
Models of Pathogenesis
In Vitro Models The extracellular matrix consists of base-
ment membrane and interstitial connective tissue, dominated
by the three-dimensional (3D) network of collagen I fibers
[134]. Fibrillar collagen is the most abundant protein of the
extracellular matrix, others being elastin, fibronectin, and
laminins. The visualization and interpretation of these 3D col-
lagen matrices using advanced techniques of 3D time lapse
microscopy [135] has provided a great boost in understanding
pathogenesis. The 3D collagen architecture with or without
intestinal epithelial cells (mostly using epithelial tumor cells)
define mechanical properties of tissues and provide models
which partially mimics the way amoeba invade through base-
ment membrane in the intestine. Thibeaux et al. showed that
collagenolytic activity important for amoebic invasion is
mainly due to the CPs, particularly EhCP5 [136], and that
the parasite follows amoeboid migration through the
3D collagen matrix and has unique features as com-
pared to mesenchymal and small cells, such as T lym-
phocytes and dendritic cells. In a dense 3D collagen
matrix, amoebic cells adopt a protease- and amoeboid-
dependent mode of migration [136, 137].
During liver invasion, E. histolytica trophozoites are in
contact with liver sinusoidal endothelial cells (LSEC). A
LSEC cell line has been generated from immortalized cells
of human liver endothelial cell primary cultures [138]. Cells
do not transform and express phenotypic markers of primary
cultures [139] and respond to inflammatory molecules such as
TNF [140] and to hypoxia/reoxygenation stress by inducing
necrosis and apoptosis [141]. Incubation of virulent trophozo-
ites of E. histolytica with LSEC interfered with host cell ad-
hesion signaling and leads to diminished adhesion and target
cell death. This is a direct result of contact with parasites that
induces the disruption of actin stress fibers and focal adhesion
complexes of target residues [142]. A 3D in vitro liver model
generated using a monolayer of Huh-7 hepatocytic cells em-
bedded in a 3D COL-I matrix and an LSEC monolayer plated
on top of the matrix was incubated with trophozoites and
monitored by two-photon microscopy. This model revealed
the role of human galectins in aiding invasion. Human
galectins have been reported earlier to play a role in innate
immune response to microbial infections. Human galectins 1
and 3 play a dual role: promoting hepatic adhesion and then
triggering a pro-inflammatory response in hepatic infection by
E. histolytica [143•]. Some of the amoebic factors that appear
to participate are Gal/GalNAc lectin, cysteine proteases, and
KERP1.
Animal Models Animal models, such as mice models of
amoebic colitis and gerbil model of liver abscess, have been
extensively used to study amoebic pathogenesis. Mice carry-
ing this humanized Lepr 223R allele using homologous re-
combination (equivalent to 222R in the mouse; for simplicity,
it will be referred to as 223R) were generated by injecting ES
clone into C57BL/6J blastocysts [26•, 144]. The amoebae
were injected intracecally and the transfected cell lines were
mixed in 1:1 ratio. This induction was maintained for 4 days
and then sacrificed post 4 days of infection, and amoebae were
isolated from luminal gut and mucosal surface of mice. These
studies helped to confirm a relation between amoebic invasion
and leptin receptor. Cells overexpressing the kinase dead mu-
tant of EhTMKB1-9 showed its inability to survive and did
not show invasive phenotype in murine model of amoebic
colitis [145, 146].
In the gerbil model liver, abscesses are induced by injecting
trophozoites in different lobes of 50–60-day-old Mongolian
male gerbil. These are sacrificed 7 days post infection and the
abscess weights measured [146]. Though EhTMKB1-9 did
show its involvement in tissue invasion in the mice model,
there was no effect seen in the gerbil model [146]. Similarly,
amoebae overexpressing EhCP-2 induced monolayer destruc-
tion in vitro but did not show any marked effect on liver
abscess formation in gerbils [86]. Guinea pig model of intes-
tinal amoebiasis was generated by intracecal injection of
E. histolytica in 4–6-week-old cholesterol-fed animals, and it
consistently produced amebomas [147]. This model has been
used to see the effect of heparin sulfate-binding proteins of
E. histolytica. These were found to provide partial protection
against challenged infection [148]. Unavailability of good an-
imal models precludes detailed study on the progression of
this disease and is difficult to monitor.
Ex Vivo Models These provide intermediate complexity be-
tween in vitro and animal models. The results can explain
some of the features that mimic a potential tissue. Cysteine
protease-deficient E. histolytica showed less inflammation
and degradation of tissues in the severe combined immunode-
ficient mouse/human intestinal xenograft (SCID-HU-INT)
model of amoebic colitis [95, 149]. CPs mimicked the inter-
leukin 1-beta-converting enzyme activity of human and
breaks down interleukins [95]. Bansal et al. used human colon
explants for the first time to show that dynamics of tissue
invasion, destruction, and induction of early inflammatory
response can be reproduced [150, 151••]. Porcine colonic ex-
plants [152•] behave in the same ways as the human colonic
explants. Studies on human colon explants also suggest car-
bohydrate sources may affect the ability to invade the intestine
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[137]. Precision cut liver slices has been proposed as a useful
model for studying amoebic liver abscess [153, 154]. It is
possible to observe cytokine production and apoptosis after
incubation with E. histolytica and study mechanisms using
this model.
This brings out an important issue of using multiple
models, as a single model may not give accurate picture as
none of the models do really reflect actual infection cycle in
humans (by cysts through oral route).
Conclusion
The pathogenesis of amoebiasis involves interplay of various
molecules secreted by E. histolytica such as LPPG, lectins,
cysteine proteases, and amoebapores. Lectins help in the at-
tachment of the parasite to the mucosal layer of the host during
invasion. The amoebapores destroy the ingested bacteria pres-
ent in the colonic environment. Cysteine proteases lyse the
host tissues. Other molecules such as PATMK, myosins, G
proteins, C2PK, CaBP3, and EhAK1 play an important role
in the process of phagocytosis. Unraveling of new molecules
in understanding the process of phagocytosis will help a great
deal in developing therapeutics for this disease, but there are
still many questions that remain unanswered. We have also
seen that host genotype also play an important role in suscep-
tibility of the infection. All the animal models available till
now have not been able to replicate the actual infection cycle
in the humans. Extensive work has been done in understand-
ing the complex mechanisms of infection, but there still a long
way to go before we could completely understand the basis of
the pathogenesis.
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